PDCD1 and melanoma: In a Phase I clinical trial (NCT03005782) evaluating the combination of Fianlimab with the anti-PD-1 antibody Cemiplimab in patients with advanced melanoma, 98 participants were administered Fianlimab (1600 mg) and Cemiplimab (350 mg) every three weeks over a period of 12 months.